IAR129 / Innovent Biologics - LARVOL DELTA

Development and characterization of IAR129, a novel bispecific antibody co-blocking IL-4Ra and OX40L for atopic dermatitis (EADV 2025) - "IAR129 is a first-in class IL4R and OX40L bispecific antibody with half life extension. It potently blocks IL-4, IL-13 and OX40L in vitro comparable to dupilumab and amlitelimab. It shows combinatorial activity superior to single blockade in DC-T coculture, and is highly effective in suppressing both airway inflammation and atopic dermatitis in mice."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Respiratory Diseases • IL13 • IL2 • IL4R • IL5 • TNFSF4 • TSLP

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025 (PRNewswire) - "Specifically, post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (IL-23p19 monoclonal antibody, picankibart), as well as preclinical study results of IBI3013 (IL-15 monoclonal antibody) and IAR129 (IL-4R/OX40L bispecific antibody) will be showcased via ePoster."

Clinical data • Preclinical • Atopic Dermatitis • Psoriasis